



Amended Claims

Claims 1-70 (canceled).

71. (currently amended) A compound of the Formula I:



or a pharmaceutically acceptable salt thereof, wherein:





is a thiazole or isoxazole, **wherein:**

the thiazole or isoxazole is optionally substituted with one or more substituents **independently** selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, thioalkyl, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$;

each m is **independently zero, 1, or 2**;



each R is **independently** selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A^1 is selected from the group consisting of:





~~$X = CH_2, O, S, SO_2, CO, CF_2, CMe_2$~~

~~$R = H, Me, OMe, OH, NR_2$~~



~~$X = CH_2, O, S, SO_2, CO, CF_2, CMe_2$~~

~~$R = H, Me, OMe, OH, NR_2$ and~~



~~$X = CH_2, O, S, SO_2, CO, CMe_2$~~

~~$R = H, Me, OMe, OH;$~~

wherein any such substituent is optionally substituted by one or more substituents
independently $[[R^k]]$ selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl,
thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and $-COR^4$;

X^{10} is $CH_2, O, S, SO_2, CO, CF_2$, or $C(CH_3)_2$;

X¹¹ is CH₂, O, S, SO₂, CO, CF₂, or C(CH₃)₂;

X¹² is CH₂, O, S, SO₂, CO, or C(CH₃)₂;

R¹⁰ is H, CH₃, OCH₃, OH, or NR₂;

R¹¹ is H, CH₃, OCH₃, OH, or NR₂;

R¹² is H, CH₃, OCH₃, or OH;

each R⁴ is independently hydroxy, alkoxy, alkyl, or amino;

as to Z₁ and Z₂:

Z₁ is selected from the group consisting of CH₂, O, CH₂O, NH, CO, S, SO, CH(OH), and SO₂; and Z₂ is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; or

Z₁ - Z₂ contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or

Z₁ - Z₂ contains a 5- or 6-membered aryl or heteroaryl ring, wherein:

the heteroaryl ring optionally is substituted with R^c, and wherein

the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;

each R^c is independently selected from the group consisting of [[H,]] alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano; wherein

the carbon and nitrogen atoms of Z₁ - Z₂ are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

as to X and Y:

X-Y contains a moiety selected from the group consisting of acyl, alkyl, sulfonyl, amino, ether, thioether, carboxamido, sulfonamido, aminosulfonyl and olefins; or

X is selected from the group consisting of -CHR^e-, -NR^f-, -O-, -S-, -SO₂-, and -CO-; and Y is selected from the group consisting of (CH₂)_p, -CHR^g-, -NR^g-, CO, and SO₂;

R^e is selected from the group consisting of H, lower alkyl, alkoxy, cycloalkyl, alkoxyalkyl, hydroxy, alkynyl, alkenyl, haloalkyl, thioalkyl, and aryl, [[;]] wherein;

when R^e is hydroxy, the hydroxy group can optionally form a lactone with the carboxylic acid function of the chain;

R^f is selected from the group consisting of H, alkyl, aryl, benzyl, and haloalkyl;

~~Y is selected from the group consisting of (CH₂)_p, CHR^g, NR^g, CO and SO₂;~~

each R^g is **independently** selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, hydroxy, alkoxy, and carboxyalkyl;

p is **zero** [[0]] or 1;

as to Y³ and Y⁴:

Y³ and Y⁴ are independently selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, aralkyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, [[;]] wherein:

the alkyl chain is straight or branched and optionally contains one or more moieties **independently** selected from the group consisting of N, O, [[and]] S, sulfone, sulfoamide, nitrile, carboxamide, carboalkoxy, **and** ;

wherein

the aryl and heteroaryl rings:

are monocyclic or bicyclic optionally containing 1-5 heteroatoms,


and wherein said ring

may be saturated or unsaturated, and **such rings**

may optionally be substituted by one or more **substituent** R^c

substituents; or with the proviso that

Y³ and Y⁴ together form a 3-8 membered monocyclic or a 7-11 membered bicyclic ring B such that the compound of Formula I corresponds in structure to formula IA:



wherein ring B:

optionally contains one or more double bonds,

optionally contains one or more moieties independently selected from the group consisting of O, NR^g, S, CO, and SO₂, and

optionally is substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, halogen, haloalkyl, alkoxy, alkyne, cyano, alkylsulfone, sulfonamide, carboalkoxy, and carboxyalkyl;

Y⁵ is C or N when Y³ or Y⁴ is H; ~~Y⁵ may be C or N, otherwise~~

Y⁵ is C when Y³ and Y⁴ are both other than H; [[and]]

R^b is X₂ - R^h; ~~wherein~~

X₂ is selected from the group consisting of O, S, and NR^j; and ~~wherein~~

R^h and R^j are independently selected from the group consisting of H, alkyl, aryl, aralkyl, acyl, and alkoxyalkyl.

72. (currently amended) A compound according to claim 71, wherein:

X is ~~[[of]]~~ -CHR^e-; ~~wherein~~

R^e is H;


Y is -(CH₂)_p; ~~wherein~~

p is zero ~~[[= 0]]~~;


Y⁵ is a carbon; and

R^b is OH.

73. (currently amended) A compound ~~according to Claim 72~~ of the following formula:






or a pharmaceutically acceptable salt thereof, wherein:



is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, thioalkyl, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$;
each m is independently zero, 1, or 2;
each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A¹ is selected from the group consisting of:



wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and -COR⁴;

X¹⁰ is CH₂, O, S, SO₂, CO, CF₂, or C(CH₃)₂;

X¹¹ is CH₂, O, S, SO₂, CO, CF₂, or C(CH₃)₂;

X¹² is CH₂, O, S, SO₂, CO, or C(CH₃)₂;

R¹⁰ is H, CH₃, OCH₃, OH, or NR₂;

R¹¹ is H, CH₃, OCH₃, OH, or NR₂;

R¹² is H, CH₃, OCH₃, or OH;

each R⁴ is independently hydroxy, alkoxy, alkyl, or amino;

as to Z₁ and Z₂;

Z₁ is selected from the group consisting of CH₂, O, CH₂O, NH, CO, S, SO, CH(OH), and SO₂; and Z₂ is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; or

Z₁ - Z₂ contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or

Z₁ - Z₂ contains a 5- or 6-membered aryl or heteroaryl ring, wherein:



the heteroaryl ring optionally is substituted with R^c, and

the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;

each R^c is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;




the carbon and nitrogen atoms of Z₁ - Z₂ are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

~~Y³ or Y⁴~~ is independently selected from the group consisting of H, alkyl, CH₂B₁R²⁰, CH₂OH, C≡C-R²¹,




R₁ = H, alkyl, OMe

~~OH, halogen, amino, CN~~




X = CH₂, O




$R_1 = \text{H, alkyl, OMe}$

~~OH, halogen, amino, CN~~




$R_1 = \text{H, alkyl, OMe}$

~~OH, halogen~~



$X = \text{NH, NMe, O, S}$



~~H, alkyl, CH₂B₁R~~

B_1 is ~~[[=]] O, SO₂, S, or CO;~~

R^{20} is ~~[[=]] alkyl or [[,]] aryl;), CH₂OH, and ~~—≡—R~~ {~~

R^{21} is ~~[[=]] alkyl, aryl, or alkoxyalkyl; [D]]~~

R^{22} is H, alkyl, OCH₃, OH, halogen, amino, or CN;

R^{23} is H, alkyl, OCH₃, OH, halogen, amino, or CN;

R^{24} is H, alkyl, OCH₃, OH, or halogen;

X^{20} is CH₂ or O;

X^{21} is NH, NCH₃, O, or S; and


Y^4 is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, arakyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl chain is straight or branched and optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfoamide, nitrile, carboxamide, carboalkoxy, or carboxyl, and


the aryl and heteroaryl rings:

are monocyclic or bicyclic optionally containing 1-5 heteroatoms, may be saturated or unsaturated, and may optionally be substituted by one or more R^c substituents.

74. (currently amended) A compound ~~according to Claim 72~~ of the following formula:





or a pharmaceutically acceptable salt thereof, wherein:




is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, thioalkyl, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$;
each m is independently zero, 1, or 2;
each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A¹ is selected from the group consisting of:



, and



wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and -COR⁴;

X¹⁰ is CH₂, O, S, SO₂, CO, CF₂, or C(CH₃)₂;

X¹¹ is CH₂, O, S, SO₂, CO, CF₂, or C(CH₃)₂;

X¹² is CH₂, O, S, SO₂, CO, or C(CH₃)₂;

R¹⁰ is H, CH₃, OCH₃, OH, or NR₂;

R¹¹ is H, CH₃, OCH₃, OH, or NR₂;

R¹² is H, CH₃, OCH₃, or OH;

each R⁴ is independently hydroxy, alkoxy, alkyl, or amino;

as to Z₁ and Z₂:

Z₁ is selected from the group consisting of CH₂, O, CH₂O, NH, CO, S, SO, CH(OH), and SO₂; and Z₂ is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; or

Z₁ - Z₂ contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or

Z₁ - Z₂ contains a 5- or 6-membered aryl or heteroaryl ring, wherein:

the heteroaryl ring optionally is substituted with R^c, and


the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;

each R^c is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;

the carbon and nitrogen atoms of Z₁ - Z₂ are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, thioalkyl, alkylsulfone, aryl,

alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

Y^3 [[or Y^4]] is ~~independently~~ selected from the group consisting of H, methyl, phenyl, ethyl, propyl, isopropyl, phenylmethoxymethyl,



H, Me, Ph, Et, Pr, i-Pr, and CH_2OCH_2Ph


Y^4 is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, aralkyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl chain is straight or branched and optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfoamide, nitrile, carboxamide, carboalkoxy, or carboxyl, and

the aryl and heteroaryl rings:

are monocyclic or bicyclic optionally containing 1-5 heteroatoms, may be saturated or unsaturated, and may optionally be substituted by one or more R^c substituents.

75. (previously added) A compound according to claim 74, wherein A^1 is



76. (currently amended) A compound or a pharmaceutically acceptable salt thereof,
~~The method according to Claim 71~~ wherein the compound is selected from the group consisting of:

(2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

(2-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-cyclopropyl)-acetic acid;

(2-{4-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Pyridin-3-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Phenyl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid

(2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

(2-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-cyclopropyl)-acetic acid;

(2-{4-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Pyridin-3-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

Phenyl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid; and

3-Benzo[1,3]dioxol-5-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid.

77. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 71 and a pharmaceutically acceptable carrier.

78. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of Claim 76 and a pharmaceutically acceptable carrier.

79. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of Claim 71 and a pharmaceutically acceptable carrier/or additive and optionally a cytotoxic agent.

80. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of Claim 76 and a pharmaceutically acceptable carrier/or additive and optionally a cytotoxic agent.

81. **(currently amended)** A method for treating a condition ~~conditions~~ mediated by ~~[[the]]~~ $\alpha_v\beta_3$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound or salt of Claim 71.

82. **(currently amended)** A method for treating a condition ~~conditions~~ mediated by ~~[[the]]~~ $\alpha_v\beta_3$ integrin in a mammal in need of such treatment comprising ~~comprising~~ administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound or salt of ~~Claims~~ claim 76.

83. **(previously added)** The method according to Claim 81 wherein the condition treated is tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis.

84. **(previously added)** The method according to Claim 82 wherein the condition treated is tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis.

85. **(new)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 73 and a pharmaceutically acceptable carrier.

86. **(new)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of claim 73 and a pharmaceutically acceptable carrier/or additive and optionally a cytotoxic agent.

87. **(new)** A method for treating a condition mediated by $\alpha_v\beta_3$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound or salt of claim 73.

88. **(new)** The method according to Claim 87, wherein the condition treated is tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis.


89. **(new)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 74 and a pharmaceutically acceptable carrier.

90. **(new)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of claim 74 and a pharmaceutically acceptable carrier/or additive and optionally a cytotoxic agent.


91. **(new)** A method for treating a condition mediated by $\alpha_v\beta_3$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound or salt of claim 74.

92. **(new)** The method according to claim 91, wherein the condition treated is tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis.

93. **(new)** A compound of the Formula I:



or a pharmaceutically acceptable salt thereof, wherein:






is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, thioalkyl, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$;

each m is independently zero, 1, or 2;

each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A¹ is selected from the group consisting of:



wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and $-\text{COR}^4$;

X^{10} is CH_2 , O, S, SO_2 , CO, CF_2 , or $\text{C}(\text{CH}_3)_2$;

X^{11} is CH_2 , O, S, SO_2 , CO, CF_2 , or $\text{C}(\text{CH}_3)_2$;

X^{12} is CH_2 , O, S, SO_2 , CO, or $\text{C}(\text{CH}_3)_2$;

R^{10} is H, CH_3 , OCH_3 , OH, or NR_2 ;

R^{11} is H, CH_3 , OCH_3 , OH, or NR_2 ;

R^{12} is H, CH_3 , OCH_3 , or OH;

each R^4 is independently hydroxy, alkoxy, alkyl, or amino;

as to Z_1 and Z_2 :

Z_1 is selected from the group consisting of CH_2 , O, CH_2O , NH, CO, S, SO, $\text{CH}(\text{OH})$, and SO_2 ; and Z_2 is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; or

$\text{Z}_1 - \text{Z}_2$ contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or

$\text{Z}_1 - \text{Z}_2$ contains a 5- or 6-membered aryl or heteroaryl ring, wherein:

the heteroaryl ring optionally is substituted with R^c , and

the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;

each R^c is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;


the carbon and nitrogen atoms of $\text{Z}_1 - \text{Z}_2$ are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

Y is selected from the group consisting of $(\text{CH}_2)_p$, $-\text{CHR}^b$ -, $-\text{NR}^b$ -, CO, and SO_2 ;

each R^b is independently selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, hydroxy, alkoxy, and carboxyalkyl;

p is zero or 1;

X and Y³ together form a 3-7 membered monocyclic ring C such that the compound of Formula I corresponds in structure to formula IB:



wherein ring C:

optionally contains one or more double bonds,

optionally contains one or more moieties independently selected from the group consisting of O, NR^g, S, CO, and SO₂, and

optionally is substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, alkoxy, haloalkyl, hydroxyalkyl, and alkoxyalkyl;

Y⁴ is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, aralkyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl chain is straight or branched and optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfoamide, nitrile, carboxamide, carboalkoxy, or carboxyl, and

the aryl and heteroaryl rings:

are monocyclic or bicyclic optionally containing 1-5 heteroatoms,

may be saturated or unsaturated, and

may optionally be substituted by one or more R^c substituents; or

R^b is X₂ - R^h;

X₂ is selected from the group consisting of O, S, and NR^j; and

R^h and R^j are independently selected from the group consisting of H, alkyl, aryl, aralkyl, acyl, and alkoxyalkyl.

94. **(new)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 93 and a pharmaceutically acceptable carrier.

95. **(new)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of claim 93 and a pharmaceutically acceptable carrier/or additive and optionally a cytotoxic agent.

96. **(new)** A method for treating a condition mediated by $\alpha_v\beta_3$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound or salt of claim 93.

97. **(new)** The method according to claim 96, wherein the condition treated is tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis.